UNASSIGNED:为了确定在我们机构接受经口激光显微手术治疗的口鼻咽癌患者的5年生存结果。
UNASSIGNED:分析了2014年9月1日至2019年12月31日在我们机构诊断的所有口咽鳞状细胞癌或临床未知的原发性病例的前瞻性纵向队列研究,并接受了经口激光显微手术治疗。先前有头颈部放疗史的患者被排除在分析之外。Kaplan-Meier存活曲线用于估计5年总生存期,疾病特异性生存,本地控制,口咽鳞癌的无复发生存率。
未经批准:在确定的142名患者中,135项符合标准并纳入生存分析。p16阳性和阴性疾病的5年局部控制率分别为99.2%和100%,分别,在p16阳性队列中有一个局部失败。5年总生存率,疾病特异性生存,p16阳性疾病的无复发生存率为91%,95.2%,分别为87%(n=124)。5年总生存率,疾病特异性生存,p16阴性疾病的无复发生存率为39.8%,58.3%,60%,分别(n=11)。永久性胃造瘘管率为1.5%,零患者在手术时接受了气管造口术。一名患者(0.74%)要求返回OR进行术后咽部出血。
UNASSIGNED:经口激光显微手术是一种安全的主要治疗方法,可以治疗口咽鳞癌,5年生存率高,尤其是在p16阳性疾病中。需要更多的随机试验来比较经口激光显微手术与初级放化疗治疗相比的生存结果和相关发病率。
未经评估:3.
UNASSIGNED: To determine the 5-year survival outcomes of patients with oropharyngeal cancer treated with transoral laser microsurgery at our institution.
UNASSIGNED: A prospective longitudinal cohort study of all cases of oropharyngeal squamous cell cancer or clinically unknown primaries diagnosed at our institution between September 1, 2014, to December 31, 2019, treated with primary transoral laser microsurgery were analyzed. Patients with a previous history of head and neck radiation were excluded from analysis. Kaplan-Meier survival curves were used to estimate 5-year overall survival, disease-specific survival, local control, and recurrence free survival rates in oropharyngeal squamous cell carcinoma.
UNASSIGNED: Of 142 patients identified, 135 met criteria and were included in the survival analysis. Five-year local control rates in p16 positive and negative disease were 99.2% and 100%, respectively, with one locoregional failure in the p16 positive cohort. Five-year overall survival, disease-specific survival, and recurrence free survival in p16 positive disease were 91%, 95.2%, and 87% respectively (n = 124). Five-year overall survival, disease-specific survival, and recurrence free survival in p16 negative disease were 39.8%, 58.3%, and 60%, respectively (n = 11). The permanent gastrostomy tube rate was 1.5% and zero patients received a tracheostomy at the time of surgery. One patient (0.74%) required a return to the OR for a post-operative pharyngeal bleed.
UNASSIGNED: Transoral laser microsurgery is a safe primary treatment option for oropharyngeal squamous cell carcinoma with high 5-year survival outcomes, notably in p16 positive disease. More randomized trials are needed to compare survival outcomes and associated morbidity in transoral laser microsurgery compared to treatment with primary chemoradiation.
UNASSIGNED: 3.